CD274 and ovarian carcinoma: The second patient with a PR was a 68-year-old woman with ovarian cancer that stained 5% for PD-L1, who was previously treated with surgery and four previous regimens, which, in total, consisted of carboplatin, paclitaxel, gemcitabine, bevacizumab, docetaxel and an investigational agent (Fig. 3c).